BriaCell Announces Update On Phase 3 Clinical Progress In Pivotal Metastatic Breast Cancer Study
Portfolio Pulse from Benzinga Newsdesk
BriaCell is progressing with its Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The trial is active at 35 sites, with the primary endpoint being overall survival. Interim data analysis is planned at 144 events, potentially leading to full approval and marketing authorization. Patient enrollment is expected to complete by mid-2025, and no serious adverse events have been reported.
October 15, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell's Phase 3 trial for Bria-IMT™ in metastatic breast cancer is advancing with 35 active sites. The trial's success could lead to full approval and marketing authorization, with interim analysis planned at 144 events. No serious adverse events reported.
The progress in the Phase 3 trial is a positive development for BriaCell, as successful interim analysis could lead to full approval and marketing authorization. The absence of serious adverse events is also a positive indicator for the trial's success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100